

AMENDED

7-5/2013/EU/WC-0004
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organisation
(International Cell)

FDA Bhawan, Kotla
Road,
New Delhi-110002
Dated: **02 APR 2025**

To

M/s. IOL Chemicals and Pharmaceuticals Ltd.,
Village Fatehgarh Channa Mansa Road (Trident Complex),
Barnala, District Barnala -148101, Punjab (India).

SUB:- Written Confirmation of **M/s. IOL Chemicals and Pharmaceuticals Ltd., Village Fatehgarh Channa Mansa Road (Trident Complex), Barnala, District Barnala -148101, Punjab (India)** as per requirement of EU for import of active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India-Amendment-Reg.


Sir,

This is with reference to your email dated 11.03.2025, wherein, you had requested for an amendment in the validity of the WCC no.-0004 issued on 27.02.2025, owing to a typo error.

In this regard, please find enclosed amended Certificate.

Please acknowledge the receipt.

Yours faithfully,


(Ranga Chandrashekar)
Joint Drugs Controller (India)

चंद्रशेखर रंगा/Chandrashekar Ranga
संयुक्त औषधि नियंत्रक (भारत) / Joint Drugs Controller (India)
केंद्रीय औषधि मानक नियंत्रण संगठन (मुख्यालय), स्वास्थ्य सेवा महानिदेशालय
C.D.S.C.O.(HQ), Dte. General of Health Services
स्वास्थ्य और परिवार कल्याण मंत्रालय / Ministry of Health and Family Welfare
एन.डी.ए. भवन, कोटला रोड, नई दिल्ली-110002 / FDA Bhawan, Kotla Road, New Delhi-110002



Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

1. Name and address of site: M/s. IOL Chemicals and Pharmaceuticals Ltd.,
Village Fatehgarh Channa Mansa Road
(Trident Complex), Barnala, District Barnala -148101,
Punjab (India).

The validity of the Written Confirmation Certificate, WC-0004 is hereby amended as follows:

In place of	Read as
17.03.2027	17.03.2028

All other conditions of Written Confirmation Certificate will remain same.

Chandrashekar

Signature

चंद्रशेखर रंगा/Chandrashekar Ranga
संयुक्त औषधि नियंत्रक (भारत) / Joint Drugs Controller (India)
केंद्रीय औषधि मानक नियंत्रण संगठन (मुख्यालय), स्वास्थ्य सेवा मंत्रालय
C.D.S.C.O.(HQ), Dte. General of Health Services
स्वास्थ्य और परिवार कल्याण मंत्रालय / Ministry of Health and Family Welfare
एफ.डी.ए. भवन, बोटला रोड, नई दिल्ली-110002 / FDA Bhawan, Kotla Road, New Delhi-110002

Stamp of the authority and date



7-5/2013/EU/WC-0004
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organisation
(International Cell)

FDA Bhawan, Kotla Road,
New Delhi-110002

Dated

27 FEB 2025

To

**M/s. IOL Chemicals and Pharmaceuticals Ltd.,
Village Fatehgarh Channa Mansa Road (Trident Complex),
Barnala, District Barnala -148101, Punjab (India).**

SUB:- Written Confirmation of **M/s. IOL Chemicals and Pharmaceuticals Ltd., Village Fatehgarh Channa Mansa Road (Trident Complex), Barnala, District Barnala -148101, Punjab (India)** as per requirement of EU for import of active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India-Reg.

Sir,

Please refer to your application no. WC/RE/2024/9147 submitted to CDSCO, Baddi Zone office, and the recommendation received from DDC (I), Baddi Zone on the above noted subject.

Written Confirmation as required for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India is herewith granted subject to the following conditions: -

1. The Active Pharmaceutical Ingredients shall confirm to Good Manufacturing Practices mentioned in the EU directives or other equivalent (GMP of WHO/ICH Q7).
2. The manufacturer is subject to regular, strict and transparent controls and to the effective enforcement of Good Manufacturing Practice, including repeated and unannounced inspections, so as to ensure a protection of public health equivalent to that in the EU.
3. The manufacturer is required to follow the Guidance document for Issue of Written Confirmation as issued by CDSCO.
4. Written Confirmation shall be produced by the Authorized Exporter as and when required by the Drug Regulatory Authority.
5. The Written Confirmation will be withdrawn in the events of non-compliance of Standards.

6. This Written Confirmation, unless it is sooner suspended or cancelled, shall be valid for a period of three years.
7. In the event of any Non-Compliance observed during inspections conducted by Local or International Drug Authorities, the same shall be forwarded to this office within 7 days of receipt of report.
8. In the event of any drug found not of standard quality, the same shall be reported to this office within 7 days of receipt of report.
9. The manufacturer is required to comply to the provision of GSR 20(E) dated 18.01.2022.

Please note that Written Confirmation issued is liable to be suspended / cancelled, if any of the conditions stipulated above are not complied with or in case of violation of the provisions of the Drugs & Cosmetics Act, 1940 and the Rules thereunder as the case may be.

Please acknowledge the receipt.

Annexure No.	No. of Products	Date of Issue	Valid Upto
--	--		17.03.2027
01	11	27 FEB 2025	17.03.2027
02	02	27 FEB 2025	17.03.2027

Yours faithfully,

Chandrashekar
27/2/25
(Ranga Chandrashekar)
Joint Drugs Controller (India)

चंद्रशेखर रंगा/Chandrashekar Ranga
संयुक्त औषधि नियंत्रक (भारत) / Joint Drugs Controller(India)
केंद्रीय औषधि मानक नियंत्रण संगठन (पुष्पालय), स्वास्थ्य सेवा महानिदेशालय
C.D.S.C.O(HQ), Dte. General of Health Services
स्वास्थ्य और परिवार कल्याण मंत्रालय / Ministry of Health and Family Welfare
एन.टी.ए. भवन, कोटला रोड, नई दिल्ली-110002 / FDA Bhawan, Kotla Road, New Delhi-110002



Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

1. Name and address of site: M/s. IOL Chemicals and Pharmaceuticals Ltd.,
Village Fatehgarh Channa Mansa Road
(Trident Complex), Barnala,
District Barnala -148101, Punjab (India)

2. Manufacturer's licence number: 1689-OSP

Regarding the manufacturing plant under (1) of the following Active substance(s) exported to the EU for medicinal products for human use

List of API(s):

as per list enclosed as Annexures

The issuing Regulatory Authority hereby confirms that:

The standards of good manufacturing practice applicable to this manufacturing plant are at least equivalent to those laid down in the EU (= GMP of WHO/ICH Q7);

The manufacturing plant is subject to regular, strict and transparent controls and to the effective enforcement of good manufacturing practice, including repeated and unannounced inspections, so as to ensure a protection of public health at least equivalent to that in the EU; and

In the event of findings relating to non-compliance, information on such findings is supplied by the exporting third country without delay to the EU.

Date of Inspection of the plant: 23.01.2023 & 24.01.2023

The Written Confirmation remains valid until: 17.03.2027

The authenticity of this written confirmation may be verified with the issuing regulatory authority.

This written confirmation is without prejudice to the responsibilities of the manufacturer to ensure the quality of the medicinal product in accordance with Directive 2001/83/EC.

Address of the issuing regulatory authority: Central Drugs Standard Control Organisation

FDA Bhawan, Kotla Road,
New Delhi- 110 002, India

Name and function of responsible person: Ranga Chandrashekar,
Joint Drugs Controller (India)

E-mail:

ranga.cs@cdsco.nic.in;

Telephone no.:

+91-11-23236965


Fax no.:

+91-11-23236973

Chandrashekar

Signature

चंद्रशेखर रंगा/Chandrashekar Ranga
संयुक्त औषधि नियंत्रक (भारत) / Joint Drugs Controller (India)
केंद्रीय औषधि मानक नियंत्रण संगठन (मुख्यालय), स्वास्थ्य सेवा महानिदेशालय
C.D.S.C.O.(HQ), Dte. General of Health Services
स्वास्थ्य और परिवार कल्याण मंत्रालय / Ministry of Health and Family Welfare
एफ.डी.ए. भवन, कोटला रोड, नई दिल्ली-110002 / FDA Bhawan, Kotla Road, New Delhi-110002



Stamp of the authority and date

27 FEB 2025



GOVERNMENT OF INDIA
MINISTRY OF HEALTH & FAMILY WELFARE
Central Drugs Standard Control Organization

Annexure -01
WC-0004
CERTIFICATE NO. :

Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

1. Name and address of site: M/s. IOL Chemicals and Pharmaceuticals Ltd.,
Village Fatehgarh Channa Mansa Road
(Trident Complex), Barnala,
District Barnala -148101, Punjab (India)

List of API(s):

Sr. No.	Active substance (s)	Activity(ies)
1.	Clopidogrel Bisulfate USP	Manufacturing & Packing
2.	Dex-Ibuprofen IH	Manufacturing & Packing
3.	Fenofibrate BP/IP/USP/Ph.Eur.	Manufacturing & Packing
4.	Gabapentin BP/IP/USP/Ph.Eur.	Manufacturing & Packing
5.	Ibuprofen BP/IP/USP/Ph.Eur./JP	Manufacturing & Packing
6.	Lamotrigine BP/IP/USP/Ph.Eur.	Manufacturing & Packing
7.	Levetiracetam BP/IP/USP/Ph.Eur.	Manufacturing & Packing
8.	Losartan Potassium BP/IP/USP/Ph.Eur.	Manufacturing & Packing
9.	Metformin Hydrochloride BP/IP/USP/Ph.Eur.	Manufacturing & Packing
10.	Pantoprazole Sodium IP/USP	Manufacturing & Packing
11.	Paracetamol BP/IP/Ph.Eur.	Manufacturing & Packing

ITEM(S) ELEVEN (11) ONLY

The Written Confirmation remains valid until: 17.03.2027

Chandrashekar Ranga

Signature

चंद्रशेखर रंगा/Chandrashekar Ranga

संयुक्त औषधि नियंत्रक (भारत) / Joint Drugs Controller(India)

केंद्रीय औषधि मानक नियंत्रण संगठन (मुख्यालय), स्वास्थ्य सेवा महानिदेशालय

C.D.S.C.O.(HQ), Dte. General of Health Services

स्वास्थ्य और परिवार कल्याण मंत्रालय / Ministry of Health and Family Welfare

एफ.डी.ए. भवन, कोटला रोड, नई दिल्ली-110002 / FDA Bhawan, Kotla Road, New Delhi-110002



Stamp of the authority and date

27 FEB 2025



GOVERNMENT OF INDIA
MINISTRY OF HEALTH & FAMILY WELFARE
Central Drugs Standard Control Organization

Annexure -02
WC-0004

CERTIFICATE NO. :

Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

1. Name and address of site: M/s. IOL Chemicals and Pharmaceuticals Ltd.,
Village Fatehgarh Channa Mansa Road
(Trident Complex), Barnala,
District Barnala -148101, Punjab (India)

List of APIs:

Sr. No.	Active substance (s)	Activity(ies)
1.	Ibuprofen Lysinate IH	Manufacturing & Packing
2.	Ibuprofen Sodium IH	Manufacturing & Packing

ITEM(S) TWO (02) ONLY

This certificate is being issued subject to condition that the firm shall obtain NOC from the Competent Authority, on case to case basis, to manufacture the above-mentioned active substances for the purpose of export only, as the above-mentioned active substances are not approved for manufacture for sale in India.

The Written Confirmation remains valid until: 17.03.2027

Chandrashekar Ranga

Signature

चंद्रशेखर रंगा/Chandrashekar Ranga
संयुक्त औषधि नियंत्रक (भारत) / Joint Drugs Controller(India)
केंद्रीय औषधि मानक नियंत्रण संगठन (मुख्यालय), स्वास्थ्य सेवा महानिदेशालय
C.D.S.C.O(HQ), Dte. General of Health Services
स्वास्थ्य और परिवार कल्याण मंत्रालय / Ministry of Health and Family Welfare
एफ.डी.ए. भवन, कोटला रोड, नई दिल्ली-110002 / FDA Bhawan, Kotla Road, New Delhi-110002



Stamp of the authority and date

27 FEB 2025

7-5/2013/EU/WC-0004
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organisation
(International Cell)

FDA Bhawan, Kotla Road,
New Delhi-110002

Dated

24 JUL 2025

To

**M/s. IOL Chemicals and Pharmaceuticals Ltd.,
Village Fatehgarh Channa Mansa Road (Trident Complex),
Barnala, District Barnala -148101, Punjab (India)**

SUB:- Written Confirmation of **M/s. IOL Chemicals and Pharmaceuticals Ltd., Village Fatehgarh Channa Mansa Road (Trident Complex), Barnala, District Barnala -148101, Punjab (India)** as per requirement of EU for import of active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India-Reg.

Sir,

Please refer to your application no. **WC/ED2025/10235** submitted to CDSCO, Baddi Zone office, and the recommendation received from DDC (I), Baddi Zone on the above noted subject.

Written Confirmation as required for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India is herewith granted subject to the following conditions: -

1. The Active Pharmaceutical Ingredients shall confirm to Good Manufacturing Practices mentioned in the EU directives or other equivalent (GMP of WHO/ICH Q7).
2. The manufacturer is subject to regular, strict and transparent controls and to the effective enforcement of Good Manufacturing Practice, including repeated and unannounced inspections, so as to ensure a protection of public health equivalent to that in the EU.
3. The manufacturer is required to follow the Guidance document for Issue of Written Confirmation as issued by CDSCO.
4. Written Confirmation shall be produced by the Authorized Exporter as and when required by the Drug Regulatory Authority.
5. The Written Confirmation will be withdrawn in the events of non-compliance of Standards.

6. This Written Confirmation, unless it is sooner suspended or cancelled, shall be valid for a period of three years.
7. In the event of any Non-Compliance observed during inspections conducted by Local or International Drug Authorities, the same shall be forwarded to this office within 7 days of receipt of report.
8. In the event of any drug found not of standard quality, the same shall be reported to this office within 7 days of receipt of report.
9. The manufacturer is required to comply to the provision of GSR 20(E) dated 18.01.2022.

Please note that Written Confirmation issued is liable to be suspended / cancelled, if any of the conditions stipulated above are not complied with or in case of violation of the provisions of the Drugs & Cosmetics Act, 1940 and the Rules thereunder as the case may be.

Please acknowledge the receipt.

Annexure No.	No. of Products	Date of Issue	Valid Upto
--	--	27.02.2024	17.03.2028
01	11	27.02.2024	17.03.2028
02	02	27.02.2024	17.03.2028
--	Amendment	02.04.2025	17.03.2028
03	04	24 JUL 2025	17.03.2028

Yours faithfully,

Chandrashekar

(Ranga Chandrashekar)

Joint Drugs Controller (India)

चंद्रशेखर रंगा/Chandrashekar Ranga

संयुक्त औषधि नियंत्रक (भारत) / Joint Drugs Controller (India)

केंद्रीय औषधि मानक नियंत्रण संगठन (मुख्यालय), स्वास्थ्य सेवा महानिदेशालय

C.D.S.C.O.(HQ), Dte. General of Health Services

स्वास्थ्य और परिवार कल्याण विभाग / Ministry of Health and Family Welfare

एन.डी.ए. भवन, कोटला रोड, नई दिल्ली-110002 / FDA Bhawan, Kotla Road, New Delhi-110002



GOVERNMENT OF INDIA
MINISTRY OF HEALTH & FAMILY WELFARE
Central Drugs Standard Control Organization

CERTIFICATE NO. : Annexure -03
WC-0004

Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

1. Name and address of site: M/s. IOL Chemicals and Pharmaceuticals Ltd.,
Village Fatehgarh Channa Mansa Road
(Trident Complex), Barnala,
District Barnala -148101, Punjab (India)

List of API(s):

Sr. No.	Active substance (s)	Activity(ies)
1.	Acetaminophen USP	Manufacturing & Packing
2.	Clopidogrel Bisulphate IP	Manufacturing & Packing
3.	Clopidogrel Hydrogen Sulfate BP/Ph.Eur.	Manufacturing & Packing
4.	Pantoprazole Sodium Sesquihydrate BP/Ph.Eur.	Manufacturing & Packing

ITEM(S) FOUR (04) ONLY

The Written Confirmation remains valid until: 17.03.2028

Chandrashekar Ranga

Signature

चंद्रशेखर रंगा/Chandrashekar Ranga
संयुक्त औषधि नियंत्रक (भारत) / Joint Drugs Controller(India)
केन्द्रीय औषधि भवन नियंत्रण संगठन (मुख्यालय), स्वास्थ्य सेवा महानिदेशालय
C.D.S.C.O.(HQ), Dte. General of Health Services
स्वास्थ्य और परिवार कल्याण मंत्रालय / Ministry of Health and Family Welfare
एक डी ए भवन, कोटला रोड, नई दिल्ली-110002 / FDA Bhawan, Kotla Road, New Delhi-110002

24/07/25



24 JUL 2025